Director Jorey Chernett filed a Form 4 with the SEC on November 12, 2026, disclosing a purchase of call options in Starling Oncology, Inc. (NASDAQ:STLN) on November 11, 2026, and separately noting a calculated short-swing profit the reporting person intends to disgorge to the issuer.

Key Highlights

  • Transaction: Jorey Chernett, identified as a Director and 10% Owner, purchased 1,391 call option contracts (STLN 19FEB27 $4C) on November 11, 2026, at a price of $0.8 per derivative security.
  • Underlying shares: Each contract references Common Stock, with 139,100 shares underlying the acquired options, according to the filing.
  • Option terms: The call options carry an exercise price of $4, became exercisable on November 11, 2026, and expire on February 19, 2027.
  • Post-transaction holdings: Following the reported transaction, Chernett beneficially owned 6,391 of these derivative securities directly, the filing disclosed.
  • Short-swing profit disclosure: The filing states the transaction "is a matchable transaction subject to Section 16(b)" and that Chernett "has calculated a short-swing profit in connection with such matchable transaction, which the reporting person intends to disgorge to the Issuer."

Chernett's November 2026 Option Purchase and Section 16(b) Disgorgement Notice

According to the filing, Jorey Chernett, a Director and 10% Owner of Starling Oncology, Inc. (NASDAQ:STLN), acquired 1,391 call option contracts designated as STLN 19FEB27 $4C on November 11, 2026. The price of the derivative security was reported as $0.8. The options carry a conversion or exercise price of $4 per share and cover an aggregate of 139,100 shares of Common Stock. The options became exercisable on the transaction date and are set to expire on February 19, 2027.

Following the reported purchase, the filing indicates Chernett directly held 6,391 of these call option contracts in total. The Form 4 was filed by one reporting person and covers a single transaction date of November 11, 2026, with no Table I non-derivative securities activity reported.

Notably, the filing includes an explanation stating that the transaction "is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934," and that Chernett "has calculated a short-swing profit in connection with such matchable transaction, which the reporting person intends to disgorge to the Issuer." The filing does not specify the amount of the calculated profit.

What Was Disclosed

Jorey Chernett, a Director and 10% Owner of Starling Oncology, Inc., disclosed the purchase of 1,391 call options on November 11, 2026, at $0.8 each, with an exercise price of $4 expiring February 19, 2027, and noted a short-swing profit intended for disgorgement to the issuer.